Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function

Phase 1 Recruiting 24 enrolled Jiangsu vcare pharmaceutical technology co., LTD

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function.

Timeline

Start: 2026-04-29
Primary completion: 2026-10-30
Completion: 2026-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VC005	Unknown	25 mg	Oral

Indications

No indication recorded.